Compare Ascendis Pharma A/S (ASND) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Utilities Select Sector SPDR Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Utilities Select Sector SPDR Fund trades at $45.44. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ASND | XLU | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $47.73 |
52-Week Low | $163.32 | $40.99 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
XLU, the Utilities Select Sector SPDR ETF, trades at $45.41, up 0.62% on the day, with a bullish technical signal driven by moving averages. The ETF benefits from growing investor interest as AI-driven electricity demand transforms utilities into growth plays, with news highlighting long-term power agreements with tech firms. Key support sits at $45, while resistance is at $46. Recent dividend activity includes a $0.28 distribution scheduled for June 2026.
Outlook: XLU offers defensive exposure with upside from AI power demand, but risks include grid reliability and regulatory hurdles. Wall Street sentiment is positive due to earnings growth potential, though valuation metrics are unspecified. Investors should weigh stable dividends against infrastructure execution challenges in a shifting energy landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
